From the Research
Patient Eligibility for GLP-1 Therapy
The question of whether a patient with a precancerous polyp found on colonoscopy is a candidate for GLP-1 (Glucagon-like peptide-1) therapy requires consideration of several factors, including the potential risks and benefits of GLP-1 therapy in patients with precancerous lesions.
Risks Associated with GLP-1 Therapy
- There is evidence to suggest that GLP-1 receptor agonists may increase the risk of colorectal cancer 1.
- The potential mechanism for this increased risk is thought to be related to the enhancement of β cells proliferation in the pancreas via the Wnt/β-catenin pathway, which is associated with tumorigenesis in the colon 1.
Management of Precancerous Polyps
- Colonoscopy and endoscopic removal of precancerous polyps play a crucial role in colorectal cancer prevention 2.
- Optimal polyp resection techniques and management strategies are key for an effective colonoscopy practice 2.
- The resect-and-discard strategy is a promising management strategy for diminutive polyps, while cold snare polypectomy is a promising new approach for small polyp resection 2.
Considerations for GLP-1 Therapy in Patients with Precancerous Polyps
- Given the potential risks associated with GLP-1 therapy, patients with precancerous polyps may need to be carefully evaluated for their candidacy for this treatment 1.
- The benefits of GLP-1 therapy, such as improved glycemic control, must be weighed against the potential risks of increased colorectal cancer risk 1.
- Patients with a history of precancerous polyps may require closer monitoring and surveillance for colorectal cancer if they are treated with GLP-1 receptor agonists 1.